The role of eptifibatide in patients undergoing percutaneous coronary intervention

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 8, 2007, Pages 1147-1154

  Zeymer, Uwe ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Acute coronary syndrome; Eptifibatide; Glycoprotein IIb IIIa antagonist; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PLACEBO; TENECTEPLASE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; HEART INFARCTION; HEART MUSCLE REPERFUSION; HIGH RISK POPULATION; HUMAN; MONOTHERAPY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT OUTCOME;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; HUMANS; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SURGICAL PROCEDURES, ELECTIVE; THROMBOSIS;

EID: 34250633613     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.8.1147     Document Type: Article

References (23)

1. CURRAN MP, KEATING GM: Eptifibatide. A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs (2005) 65(14):2009-2035.
2. GILCHRIST IC, O'SHEA JC, KOSOGLOU T et al.: Pharmacodynamics and pharmakokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation (2001) 104:406-411.
3. THE ESPRIT INVESTIGATORS: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet (2000) 356:2037-2044.
4. KEREIAKES DJ, BRODERICK TM, ROTH EM et al.: Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary interventions. Am. J. Cardiol. (1999) 84:391-395.
5. GRETLER DD, GUERCIOLINI R, WILLIAMS PJ: Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin. Ther. (2004) 26(3):390-398.
6. THE IMPACT-II INVESTIGATORS: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet (1997) 349:1422-1428.
7. O'SHEA JC, BULLER CE, CANTOR WJ et al.: Long-term efficacy of pletelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA (2002) 287:618-621.
8. THE PRICE INVESTIGATORS: Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. Am. Heart J. (2001) 141:402-409.
9. KASTRATI A, MEHILI J, SCHÜHLEN H et al.: A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med. (2004) 350:232-238.
10. THE PURSUIT INVESTIGATORS: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N. Engl. J. Med. (1998) 339(7):436-443.
11. LINCOFF AM, HARRINGTON RA, CALIFF RM et al.: Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition: insights from the Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. Circulation (2000) 102:1093-1100.
12. GIUGLIANO RP, NEWBY LK, HARRINGTON RA et al.: The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome - study design and rationale. Am. Heart J. (2005) 149(6):994-1002.
13. BHATT DL, TOPOL EJ: Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA (2000) 284:1549-1558.
14. KASTRATI A, MEHILI J, NEUMANN J et al.: Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention. JAMA (2006) 295:1531-1536.
15. STONE GW, MC LAURIN BT, COX DA et al.: Bivalirudin for patients with acute coronary syndromes. N. Engl. J. Med. (2006) 355:2203-2216.
16. CUTLIP DE, COVE CJ, IRONS D et al.: Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarcrion and its effect on baseline coronary flow and procedure outcomes. Am. J. Cardiol. (2001) 88:62-64.
17. ZEYMER U, ZAHN R, SCHIELE R et al.: Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur. Heart J. (2005) 26:1971-1977.
18. GIBSON CM, KIRTANE AJ, MURPHY SA et al.: Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am. Heart J. (2006) 152:668-675.
19. THE ADVANCE MI INVESTIGATORS: Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated Adressing the Value of facilitated Angioplasty after combination therapy or Eptifibatide monotherapy in acute Myocardial infarction trial (ADVANCE MI) trial. Am. Heart J. (2005) 150:116-122.
20. BHATT DL, MARSO SP, LINCOOF AM et al.: Abciimab reduces mortality in diabetics following percutancous coronary intervention. J. Am. Coll. Cardiol. (2000) 35:922-928.
21. BRAUNWALD E, ANTMAN EM, BEASLEY JW et al.: ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002. Circulation (2002) 106(14):1893-1900.
22. BERTRAND ME, SIMOONS ML, FOX KA et al.: Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. (2002) 23:1809-1840.
23. SILBER S, ALBERTSSON P, AVILES FF et al.: Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur. Heart J. (2005) 26(8):804-847.